GC
XENE icon

Guggenheim Capital’s Xenon Pharmaceuticals XENE Stock Holding History

Guggenheim Capital’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,019
Closed -$202K – 1684
2025
Q1 		$202K Sell
6,019
-158
-3% -$6K ﹤0.01% 1534
2024
Q4 		$242K Sell
6,177
-4,452
-42% -$184K ﹤0.01% 1526
2024
Q3 		$418K Sell
10,629
-661
-6% -$26.7K ﹤0.01% 1475
2024
Q2 		$440K Sell
11,290
-98
-0.9% -$3.92K ﹤0.01% 1492
2024
Q1 		$490K Buy
11,388
+1,859
+20% +$85.5K ﹤0.01% 1482
2023
Q4 		$439K Sell
9,529
-1,603
-14% -$56.6K ﹤0.01% 1505
2023
Q3 		$380K Buy
11,132
+758
+7% +$28.4K ﹤0.01% 1545
2023
Q2 		$399K Sell
10,374
-8,848
-46% -$352K ﹤0.01% 1561
2023
Q1 		$688K Buy
19,222
+129
+0.7% +$4.77K 0.01% 1353
2022
Q4 		$753K Buy
19,093
+4,155
+28% +$151K 0.01% 1301
2022
Q3 		$539K Buy
14,938
+561
+4% +$20.2K ﹤0.01% 1445
2022
Q2 		$437K Buy
14,377
+184
+1% +$5.57K ﹤0.01% 1629
2022
Q1 		$434K Buy
14,193
+509
+4% +$15.2K ﹤0.01% 1730
2021
Q4 		$427K Buy
13,684
+3,609
+36% +$108K ﹤0.01% 1762
2021
Q3 		$154K Buy
+10,075
New +$175K ﹤0.01% 2093

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Guggenheim Capital's XENE Position: Q2 2025 in Review

Guggenheim Capital sold out of Xenon Pharmaceuticals (XENE) in Q2 2025, closing a stake of 6,019 shares — an estimated $202K sold.

Guggenheim Capital first reported a position in XENE in Q3 2021 and held it in 15 quarters. The position peaked at $753K in Q4 2022. 206 funds tracked by Wall St. Rank hold XENE as of Q2 2025.

  • Guggenheim Capital reported no remaining Xenon Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Guggenheim Capital sold 6,019 Xenon Pharmaceuticals shares in Q2 2025, an estimated $202K.
  • Guggenheim Capital first reported a position in Xenon Pharmaceuticals in Q3 2021 and held it in 15 quarters.
  • Guggenheim Capital's Xenon Pharmaceuticals position peaked at $753K in Q4 2022.
  • 206 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2025.

Based on Guggenheim Capital's 13F filing for Q2 2025, filed 13 Aug 2025.